| 1. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J.. (2003) Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery., 46 (9): [PMID:12699389] [10.1021/jm021012t] |
| 2. Yoshida F, Topliss JG.. (2000) QSAR model for drug human oral bioavailability., 43 (13): [PMID:10891117] [10.1021/jm0000564] |
| 3. Keserü GM.. (2003) Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods., 13 (16): [PMID:12873512] [10.1016/s0960-894x(03)00492-x] |
| 4. Lee YS, Lee BH, Park SJ, Kang SB, Rhim H, Park JY, Lee JH, Jeong SW, Lee JY.. (2004) 3,4-Dihydroquinazoline derivatives as novel selective T-type Ca2+ channel blockers., 14 (13): [PMID:15177437] [10.1016/j.bmcl.2004.04.090] |
| 5. Cavalli A, Poluzzi E, De Ponti F, Recanatini M.. (2002) Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers., 45 (18): [PMID:12190308] [10.1021/jm0208875] |
| 6. Schneider G, Coassolo P, Lavé T.. (1999) Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques., 42 (25): [PMID:10602692] [10.1021/jm991030j] |
| 7. Rajamani R, Tounge BA, Li J, Reynolds CH.. (2005) A two-state homology model of the hERG K+ channel: application to ligand binding., 15 (6): [PMID:15745831] [10.1016/j.bmcl.2005.01.008] |
| 8. Rhim H, Lee YS, Park SJ, Chung BY, Lee JY.. (2005) Synthesis and biological activity of 3,4-dihydroquinazolines for selective T-type Ca2+ channel blockers., 15 (2): [PMID:15603940] [10.1016/j.bmcl.2004.10.078] |
| 9. Du LP, Tsai KC, Li MY, You QD, Xia L.. (2004) The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents., 14 (18): [PMID:15324906] [10.1016/j.bmcl.2004.06.070] |
| 10. Tobita M, Nishikawa T, Nagashima R.. (2005) A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors., 15 (11): [PMID:15911273] [10.1016/j.bmcl.2005.03.080] |
| 11. Ku IW, Cho S, Doddareddy MR, Jang MS, Keum G, Lee JH, Chung BY, Kim Y, Rhim H, Kang SB.. (2006) Morpholin-2-one derivatives as novel selective T-type Ca2+ channel blockers., 16 (19): [PMID:16876404] [10.1016/j.bmcl.2006.05.031] |
| 12. Jo MN, Seo HJ, Kim Y, Seo SH, Rhim H, Cho YS, Cha JH, Koh HY, Choo H, Pae AN.. (2007) Novel T-type calcium channel blockers: dioxoquinazoline carboxamide derivatives., 15 (1): [PMID:17035033] [10.1016/j.bmc.2006.09.051] |
| 13. Doddareddy MR, Choo H, Cho YS, Rhim H, Koh HY, Lee JH, Jeong SW, Pae AN.. (2007) 3D pharmacophore based virtual screening of T-type calcium channel blockers., 15 (2): [PMID:17074493] [10.1016/j.bmc.2006.10.013] |
| 14. Park JH, Choi JK, Lee E, Lee JK, Rhim H, Seo SH, Kim Y, Doddareddy MR, Pae AN, Kang J, Roh EJ.. (2007) Lead discovery and optimization of T-type calcium channel blockers., 15 (3): [PMID:17150365] [10.1016/j.bmc.2006.11.004] |
| 15. Singleton DH, Boyd H, Steidl-Nichols JV, Deacon M, Groot MJ, Price D, Nettleton DO, Wallace NK, Troutman MD, Williams C, Boyd JG.. (2007) Fluorescently labeled analogues of dofetilide as high-affinity fluorescence polarization ligands for the human ether-a-go-go-related gene (hERG) channel., 50 (13): [PMID:17536794] [10.1021/jm0700565] |
| 16. Seo HN, Choi JY, Choe YJ, Kim Y, Rhim H, Lee SH, Kim J, Joo DJ, Lee JY.. (2007) Discovery of potent T-type calcium channel blocker., 17 (21): [PMID:17869104] [10.1016/j.bmcl.2007.08.070] |
| 17. Choi JY, Seo HN, Lee MJ, Park SJ, Park SJ, Jeon JY, Kang JH, Pae AN, Rhim H, Lee JY.. (2007) Synthesis and biological evaluation of novel T-type calcium channel blockers., 17 (2): [PMID:17064894] [10.1016/j.bmcl.2006.10.024] |
| 18. Kim HS, Kim Y, Doddareddy MR, Seo SH, Rhim H, Tae J, Pae AN, Choo H, Cho YS.. (2007) Design, synthesis, and biological evaluation of 1,3-dioxoisoindoline-5-carboxamide derivatives as T-type calcium channel blockers., 17 (2): [PMID:17092715] [10.1016/j.bmcl.2006.10.042] |
| 19. Kornhuber J, Tripal P, Reichel M, Terfloth L, Bleich S, Wiltfang J, Gulbins E.. (2008) Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model., 51 (2): [PMID:18027916] [10.1021/jm070524a] |
| 20. Hangeland JJ, Cheney DL, Friends TJ, Swartz S, Levesque PC, Rich AJ, Sun L, Bridal TR, Adam LP, Normandin DE, Murugesan N, Ewing WR.. (2008) Design and SAR of selective T-type calcium channel antagonists containing a biaryl sulfonamide core., 18 (2): [PMID:18160281] [10.1016/j.bmcl.2007.11.103] |
| 21. Yang ZQ, Barrow JC, Shipe WD, Schlegel KA, Shu Y, Yang FV, Lindsley CW, Rittle KE, Bock MG, Hartman GD, Uebele VN, Nuss CE, Fox SV, Kraus RL, Doran SM, Connolly TM, Tang C, Ballard JE, Kuo Y, Adarayan ED, Prueksaritanont T, Zrada MM, Marino MJ, Graufelds VK, DiLella AG, Reynolds IJ, Vargas HM, Bunting PB, Woltmann RF, Magee MM, Koblan KS, Renger JJ.. (2008) Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels., 51 (20): [PMID:18817368] [10.1021/jm800830n] |
| 22. Jia L, Sun H.. (2008) Support vector machines classification of hERG liabilities based on atom types., 16 (11): [PMID:18448342] [10.1016/j.bmc.2008.04.028] |
| 23. Lee HK, Lee YS, Roh EJ, Rhim H, Lee JY, Shin KJ.. (2008) Synthesis and evaluation of alpha,alpha'-disubstituted phenylacetate derivatives for T-type calcium channel blockers., 18 (15): [PMID:18625556] [10.1016/j.bmcl.2008.06.037] |
| 24. Ermondi G, Visentin S, Caron G.. (2009) GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers., 44 (5): [PMID:19110341] [10.1016/j.ejmech.2008.11.009] |
| 25. Du-Cuny L, Song Z, Moses S, Powis G, Mash EA, Meuillet EJ, Zhang S.. (2009) Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain., 17 (19): [PMID:19734051] [10.1016/j.bmc.2009.08.022] |
| 26. Guerra A, Campillo NE, Páez JA.. (2010) Neural computational prediction of oral drug absorption based on CODES 2D descriptors., 45 (3): [PMID:20022146] [10.1016/j.ejmech.2009.11.034] |
| 27. Gu SJ, Lee JK, Pae AN, Chung HJ, Rhim H, Han SY, Min SJ, Cho YS.. (2010) Synthesis and biological evaluation of 1,4-diazepane derivatives as T-type calcium channel blockers., 20 (9): [PMID:20382529] [10.1016/j.bmcl.2010.03.084] |
| 28. Lee JE, Koh HY, Seo SH, Baek YY, Rhim H, Cho YS, Choo H, Pae AN.. (2010) Synthesis and biological evaluation of oxazole derivatives as T-type calcium channel blockers., 20 (14): [PMID:20621730] [10.1016/j.bmcl.2010.05.030] |
| 29. Kam YL, Rhee HK, Rhim H, Back SK, Na HS, Choo HY.. (2010) Synthesis and T-type calcium channel blocking activity of novel diphenylpiperazine compounds, and evaluation of in vivo analgesic activity., 18 (16): [PMID:20659804] [10.1016/j.bmc.2010.06.082] |
| 30. Mahmoudi N, Garcia-Domenech R, Galvez J, Farhati K, Franetich JF, Sauerwein R, Hannoun L, Derouin F, Danis M, Mazier D.. (2008) New active drugs against liver stages of Plasmodium predicted by molecular topology., 52 (4): [PMID:18212104] [10.1128/aac.01043-07] |
| 31. Fritch PC, Krajewski J.. (2010) Design, syntheses, and SAR of 2,8-diazaspiro[4.5]decanones as T-type calcium channel antagonists., 20 (22): [PMID:20934333] [10.1016/j.bmcl.2010.09.098] |
| 32. PubChem BioAssay data set, |
| 33. PubChem BioAssay data set, |
| 34. PubChem BioAssay data set, |
| 35. Obach RS, Lombardo F, Waters NJ.. (2008) Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds., 36 (7): [PMID:18426954] [10.1124/dmd.108.020479] |
| 36. Choi YH, Baek du J, Seo SH, Lee JK, Pae AN, Cho YS, Min SJ.. (2011) Facile synthesis and biological evaluation of 3,3-diphenylpropanoyl piperazines as T-type calcium channel blockers., 21 (1): [PMID:21126876] [10.1016/j.bmcl.2010.11.033] |
| 37. Talevi A, Goodarzi M, Ortiz EV, Duchowicz PR, Bellera CL, Pesce G, Castro EA, Bruno-Blanch LE.. (2011) Prediction of drug intestinal absorption by new linear and non-linear QSPR., 46 (1): [PMID:21112128] [10.1016/j.ejmech.2010.11.005] |
| 38. Greene N, Fisk L, Naven RT, Note RR, Patel ML, Pelletier DJ.. (2010) Developing structure-activity relationships for the prediction of hepatotoxicity., 23 (7): [PMID:20553011] [10.1021/tx1000865] |
| 39. Ekins S, Williams AJ, Xu JJ.. (2010) A predictive ligand-based Bayesian model for human drug-induced liver injury., 38 (12): [PMID:20843939] [10.1124/dmd.110.035113] |
| 40. (2008) Casarett and Doull's Toxicology The Basic Science of Poisons, 7th edition, |
| 41. Fontana E, Dansette PM, Poli SM.. (2005) Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity., 6 (1): [PMID:16248836] [10.2174/138920005774330639] |
| 42. Gozalbes R, Jacewicz M, Annand R, Tsaioun K, Pineda-Lucena A.. (2011) QSAR-based permeability model for drug-like compounds., 19 (8): [PMID:21458999] [10.1016/j.bmc.2011.03.011] |
| 43. Watanuki S, Matsuura K, Tomura Y, Okada M, Okazaki T, Ohta M, Tsukamoto S.. (2011) Synthesis and pharmacological evaluation of 1-alkyl-N-[2-ethyl-2-(4-fluorophenyl)butyl]piperidine-4-carboxamide derivatives as novel antihypertensive agents., 19 (18): [PMID:21875808] [10.1016/j.bmc.2011.07.030] |
| 44. Woo HM, Lee YS, Roh EJ, Seo SH, Song CM, Chung HJ, Pae AN, Shin KJ.. (2011) Synthesis and biological evaluation of 4-piperidinecarboxylate and 4-piperidinecyanide derivatives for T-type calcium channel blockers., 21 (19): [PMID:21843937] [10.1016/j.bmcl.2011.07.087] |
| 45. PubChem BioAssay data set, |
| 46. Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W.. (2011) Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps)., 7 (12): [PMID:22194678] [10.1371/journal.pcbi.1002310] |
| 47. Nagy H, Goda K, Fenyvesi F, Bacsó Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabó G.. (2004) Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies., 315 (1): [PMID:14985103] [10.1016/j.bbrc.2004.01.156] |
| 48. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J.. (2003) Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery., 46 (9): [PMID:12699389] [10.1021/jm021012t] |
| 49. Ekins S, Kim RB, Leake BF, Dantzig AH, Schuetz EG, Lan LB, Yasuda K, Shepard RL, Winter MA, Schuetz JD, Wikel JH, Wrighton SA.. (2002) Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein., 61 (1): [PMID:11961113] [10.1124/mol.61.5.964] |
| 50. Wandel C, Kim RB, Guengerich FP, Wood AJ.. (2000) Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A in vitro., 28 (1): [PMID:10901697] |
| 51. Rodrigues T, Prudêncio M, Moreira R, Mota MM, Lopes F.. (2012) Targeting the liver stage of malaria parasites: a yet unmet goal., 55 (3): [PMID:22122518] [10.1021/jm201095h] |
| 52. Orr ST, Ripp SL, Ballard TE, Henderson JL, Scott DO, Obach RS, Sun H, Kalgutkar AS.. (2012) Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks., 55 (11): [PMID:22409598] [10.1021/jm300065h] |
| 53. Park JE, Ji WK, Jang JW, Pae AN, Choi K, Choi KH, Kang J, Roh EJ.. (2013) Synthesis and biological evaluation of 1-(2-hydroxy-3-phenyloxypropyl)piperazine derivatives as T-type calcium channel blockers., 23 (6): [PMID:23395659] [10.1016/j.bmcl.2012.12.072] |
| 54. Giordanetto F, Wållberg A, Knerr L, Selmi N, Ullah V, Thorstensson F, Lindelöf Å, Karlsson S, Nikitidis G, Llinas A, Wang QD, Lindqvist A, Högberg G, Lindhardt E, Åstrand A, Duker G.. (2013) Discovery of N-[[1-[2-(tert-butylcarbamoylamino)ethyl]-4-(hydroxymethyl)-4-piperidyl]methyl]-3,5-dichloro-benzamide as a selective T-type calcium channel (Cav3.2) inhibitor., 23 (1): [PMID:23200256] [10.1016/j.bmcl.2012.10.140] |
| 55. Jang SJ, Choi HW, Choi DL, Cho S, Rim HK, Choi HE, Kim KS, Huang M, Rhim H, Lee KT, Lee JY.. (2013) In vitro cytotoxicity on human ovarian cancer cells by T-type calcium channel blockers., 23 (24): [PMID:24220170] [10.1016/j.bmcl.2013.10.049] |
| 56. Choi DL, Jang SJ, Cho S, Choi HE, Rim HK, Lee KT, Lee JY.. (2014) Inhibition of cellular proliferation and induction of apoptosis in human lung adenocarcinoma A549 cells by T-type calcium channel antagonist., 24 (6): [PMID:24529871] [10.1016/j.bmcl.2014.01.071] |
| 57. Han M, Song C, Jeong N, Hahn HG.. (2014) Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine., 5 (9): [PMID:25221656] [10.1021/ml500187a] |
| 58. Yun J, Han M, Song C, Cheon SH, Choi K, Hahn HG.. (2014) Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors., 24 (15): [PMID:24974340] [10.1016/j.bmcl.2014.06.026] |
| 59. Mirams GR, Cui Y, Sher A, Fink M, Cooper J, Heath BM, McMahon NC, Gavaghan DJ, Noble D.. (2011) Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk., 91 [PMID:21300721] [10.1093/cvr/cvr044] |
| 60. Wiśniowska B, Mendyk A, Fijorek K, Glinka A, Polak S.. (2012) Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment., 32 [PMID:22761000] [10.1002/jat.2784] |
| 61. Kramer J, Obejero-Paz CA, Myatt G, Kuryshev YA, Bruening-Wright A, Verducci JS, Brown AM.. (2013) MICE models: superior to the HERG model in predicting Torsade de Pointes., 3 [PMID:23812503] [10.1038/srep02100] |
| 62. Foti RS, Rock DA, Pearson JT, Wahlstrom JL, Wienkers LC.. (2011) Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction., 39 (7): [PMID:21447734] [10.1124/dmd.111.038505] |
| 63. Ren S, Zeng J, Mei Y, Zhang JZ, Yan SF, Fei J, Chen L.. (2013) Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors., 41 (1): [PMID:23033255] [10.1124/dmd.112.048264] |
| 64. Farrell TL, Poquet L, Dew TP, Barber S, Williamson G.. (2012) Predicting phenolic acid absorption in Caco-2 cells: a theoretical permeability model and mechanistic study., 40 (2): [PMID:22096083] [10.1124/dmd.111.041665] |
| 65. Renneberg D, Hubler F, Rey M, Hess P, Delahaye S, Gatfield J, Iglarz M, Hilpert K.. (2015) Discovery of novel bridged tetrahydronaphthalene derivatives as potent T/L-type calcium channel blockers., 25 (18): [PMID:26231163] [10.1016/j.bmcl.2015.07.038] |
| 66. IC50 data for the L-type calcium channel extracted from a set of literature articles, |
| 67. WHO Anatomical Therapeutic Chemical Classification, |
| 68. British National Formulary (72nd edition), |
| 69. Azimi I, Flanagan JU, Stevenson RJ, Inserra M, Vetter I, Monteith GR, Denny WA.. (2017) Evaluation of known and novel inhibitors of Orai1-mediated store operated Ca2+ entry in MDA-MB-231 breast cancer cells using a Fluorescence Imaging Plate Reader assay., 25 (1): [PMID:27856238] [10.1016/j.bmc.2016.11.007] |
| 70. Kim JH, Keum G, Chung H, Nam G.. (2016) Synthesis and T-type calcium channel-blocking effects of aryl(1,5-disubstituted-pyrazol-3-yl)methyl sulfonamides for neuropathic pain treatment., 123 [PMID:27517811] [10.1016/j.ejmech.2016.07.032] |
| 71. Morgan RE, Trauner M, van Staden CJ, Lee PH, Ramachandran B, Eschenberg M, Afshari CA, Qualls CW, Lightfoot-Dunn R, Hamadeh HK.. (2010) Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development., 118 (2): [PMID:20829430] [10.1093/toxsci/kfq269] |
| 72. Capuzzi SJ, Sun W, Muratov EN, Martínez-Romero C, He S, Zhu W, Li H, Tawa G, Fisher EG, Xu M, Shinn P, Qiu X, García-Sastre A, Zheng W, Tropsha A.. (2018) Computer-Aided Discovery and Characterization of Novel Ebola Virus Inhibitors., 61 (8): [PMID:29624387] [10.1021/acs.jmedchem.8b00035] |
| 73. Bezençon O, Heidmann B, Siegrist R, Stamm S, Richard S, Pozzi D, Corminboeuf O, Roch C, Kessler M, Ertel EA, Reymond I, Pfeifer T, de Kanter R, Toeroek-Schafroth M, Moccia LG, Mawet J, Moon R, Rey M, Capeleto B, Fournier E.. (2017) Discovery of a Potent, Selective T-type Calcium Channel Blocker as a Drug Candidate for the Treatment of Generalized Epilepsies., 60 (23): [PMID:29116786] [10.1021/acs.jmedchem.7b01236] |
| 74. Du Nguyen H, Okada T, Kitamura S, Yamaoka S, Horaguchi Y, Kasanami Y, Sekiguchi F, Tsubota M, Yoshida S, Nishikawa H, Kawabata A, Toyooka N.. (2018) Design and synthesis of novel anti-hyperalgesic agents based on 6-prenylnaringenin as the T-type calcium channel blockers., 26 (15): [PMID:30031654] [10.1016/j.bmc.2018.07.023] |
| 75. Unpublished dataset, |
| 76. Franck Touret, Magali Gilles, Karine Barral, Antoine Nougairède, Etienne Decroly, Xavier de Lamballerie, Bruno Coutard. (2020) In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication, [10.1101/2020.04.03.023846] |
| 77. Son WS, Jeong KS, Lim SM, Pae AN.. (2019) Structural hybridization of pyrrolidine-based T-type calcium channel inhibitors and exploration of their analgesic effects in a neuropathic pain model., 29 (10): [PMID:30928197] [10.1016/j.bmcl.2019.03.026] |
| 78. Kim JH, Nam G.. (2016) Synthesis and evaluation of 6-pyrazoylamido-3N-substituted azabicyclo[3,1,0]hexane derivatives as T-type calcium channel inhibitors for treatment of neuropathic pain., 24 (21): [PMID:27591007] [10.1016/j.bmc.2016.06.006] |
| 79. Maria Kuzikov, Elisa Costanzi, Jeanette Reinshagen, Francesca Esposito, Laura Vangeel, Markus Wolf, Bernhard Ellinger, Carsten Claussen, Gerd Geisslinger, Angela Corona, Daniela Iaconis, Carmine Talarico, Candida Manelfi, Rolando Cannalire, Giulia Rossetti, Jonas Gossen, Simone Albani, Francesco Musiani, Katja Herzog, Yang Ye, Barbara Giabbai, Nicola Demitri, Dirk Jochmans, Steven De Jonghe, Jasper Rymenants, Vincenzo Summa, Enzo Tramontano, Andrea R. Beccari, Pieter Leyssen, Paola Storici, Johan Neyts, Philip Gribbon, and Andrea Zaliani. (2020) Identification of inhibitors of SARS-Cov2 M-Pro enzymatic activity using a small molecule repurposing screen, [10.6019/CHEMBL4495564] |
| 80. Andrea Zaliani, Laura Vangeel, Jeanette Reinshagen, Daniela Iaconis, Maria Kuzikov, Oliver Keminer, Markus Wolf, Bernhard Ellinger, Francesca Esposito, Angela Corona, Enzo Tramontano, Candida Manelfi, Katja Herzog, Dirk Jochmans, Steven De Jonghe, Winston Chiu, Thibault Francken, Joost Schepers, Caroline Collard, Kayvan Abbasi, Carsten Claussen , Vincenzo Summa, Andrea R. Beccari, Johan Neyts, Philip Gribbon and Pieter Leyssen. (2020) Cytopathic SARS-Cov2 screening on VERO-E6 cells in a large repurposing effort, [10.6019/CHEMBL4495565] |
| 81. Nam Y, Ryu KD, Jang C, Moon YH, Kim M, Ko D, Chung KS, Gandini MA, Lee KT, Zamponi GW, Lee JY.. (2020) Synthesis and cytotoxic effects of 2-thio-3,4-dihydroquinazoline derivatives as novel T-type calcium channel blockers., 28 (11): [PMID:32327350] [10.1016/j.bmc.2020.115491] |
| 82. Byun JS,Sohn JM,Leem DG,Park B,Nam JH,Shin DH,Shin JS,Kim HJ,Lee KT,Lee JY. (2016) In vitro synergistic anticancer activity of the combination of T-type calcium channel blocker and chemotherapeutic agent in A549 cells., 26 (3.0): [PMID:26739776] [10.1016/j.bmcl.2015.12.010] |
| 83. Bernhard Ellinger, Justus Dick, Vanessa Lage-Rupprecht, Bruce Schultz, Andrea Zaliani, Marcin Namysl, Stephan Gebel, Ole Pless, Jeanette Reinshagen, Christian Ebeling, Alexander Esser, Marc Jacobs, Carsten Claussen, and Martin Hofmann-Apitius. (2021) HDAC6 screening dataset using tau-based substrate in an enzymatic assay yields selective inhibitors and activators, [10.6019/CHEMBL4808148] |
| 84. Unpublished dataset, |
| 85. Sutherland JJ, Yonchev D, Fekete A, Urban L.. (2023) A preclinical secondary pharmacology resource illuminates target-adverse drug reaction associations of marketed drugs., 14 (1): [PMID:37468498] [10.1038/s41467-023-40064-9] |
